@prefix this: . @prefix sub: . @prefix np: . @prefix dct: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix nkg: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "azathioprine tablets usp are indicated as an adjunct for the prevention of rejection in renal homotransplantation it is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms azathioprine tablets usp are indicated as an adjunct for the prevention of rejection in renal homotransplantation experience with over 16 transplants shows a 5 year patient survival of 35 to 55 but this is dependent on donor match for hla antigens anti donor or anti b cell alloantigen antibody and other variables the effect of azathioprine tablets on these variables has not been tested in controlled trials azathioprine tablets usp are indicated for the treatment of active rheumatoid arthritis ra to reduce signs and symptoms aspirin non steroidal anti inflammatory drugs and or low dose glucocorticoids may be continued during treatment with azathioprine tablets the combined use of azathioprine tablets with disease modifying anti rheumatic drugs dmards has not been studied for either added benefit or unexpected adverse effects the use of azathioprine tablets with these agents cannot be recommended"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation nkg:SymptomaticReliefIndication . bl:category bl:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "fgP3nVoHJK/buoN1E8cEVLxOeK7pG4kufzhCEb8eBsk95/EMi5aO1lqiAhD5pWVAtvo/0OwDkthagN81neoeeWDxhq8DjpT26gyzyPyLDe23YQAXXUV1LE+qB/qAKPS6gRNbtze8SLnoNA0TOEwRsHBKvq47PdfeW+PkG4Hxhu4="; npx:hasSignatureTarget this: . this: dct:created "2021-06-14T08:34:22.640+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }